Search results
Showing 1 to 11 of 11 results for hyperhidrosis
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (IPG487)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.
Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (IPG601)
Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to destroy sweat glands in the armpit.
Register an interest in this interventional procedure ...
Endoscopic thoracic sympathectomy for primary facial blushing (IPG480)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.
Social anxiety disorder: recognition, assessment and treatment (CG159)
This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
long term, and in particular the frequency and severity of compensatory hyperhidrosis. IPG480/1